Clinical trials: Stereotactic Ablative Radiotherapy
Breast Cancer
Ablative SBRT in Elderly BC Patients
Stereotactic body radiotherapy (SBRT) is a modern radiotherapy technique, through which extremely high doses of irradiation are delivered in a very precise manner, within a few fractions.
- Trial name
- EASE (NCT06523894)
- Testing
- SBRT
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University Hospital, Geneva
Non-Small Cell Lung Cancer
Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
This study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine…
- Trial name
- NCT04852588
- Testing
- Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA), Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Neoplasm Female
SBRT in Early Breast Cancer in Elderly Women
Surgical treatment represents the standard of local therapy in patients with early breast cancer, however in women over75, the comorbidities related to aging reduce the possibility of candidates for surgical treatment.
- Trial name
- NCT05071105
- Testing
- Stereotactic Body Radiation Therapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Rome Tor Vergata
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases
This study is designed to evaluate the safety of Stereotactic Ablative Radiotherapy (SBRT) in selected patients with stage I Non Small Cell Lung Cancer (NSCLC) or metastatic lung cancer to demonstrate the feasibility and risks of…
- Trial name
- sbrtlungfff (NCT01823003)
- Testing
- 34 Gy in a single fraction, 54Gy 18Gy/fr. x 3 fractions, 60Gy (12 x 5 fr.s)
- Where
- Spain
- Volunteers
- 67 people
- Sponsor
- Institut Català d'Oncologia
Prostate Cancer
Using Rectal Hydrogel Spacer for Salvage SABR in Prostate Cancer
There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy.
- Trial name
- FIRST STAR (NCT05597852)
- Testing
- SpaceOAR
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer, Oligometastases
Stereotactic Body Radiation for Prostate Oligometastases
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
- Trial name
- ORIOLE (NCT02680587)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oligometastatic Disease
Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions
This is a randomised prospective monoinstitutional study comparing radiosurgery at a total dose up to 24 Gy to five fraction stereotactic radiotherapy with simultaneous integrated boost (SIB) up to 50 Gy for the treatment of bone…
- Trial name
- ONES (NCT05679427)
- Testing
- radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively
- Where
- Italy
- Volunteers
- 307 people
- Sponsor
- IRCCS San Raffaele
Oligometastatic Disease, Bone Metastases
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
This is a prospective, investigator-initiated, phase II, multicentre-study, investigating the efficacy and toxicity of definitive SABR of osseous oligometastases, when pragmatically introduced into a daily clinical setting.
- Conditions
- Oligometastatic Disease, Bone Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT05101824
- Testing
- SABR
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 67 people
- Sponsor
- Gitte Fredberg Persson MD PhD
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer
This clinical trial compares stereotactic ablative radiotherapy (SBRT) with hot spots to standard of care SBRT for the treatment of patients with early-stage non-small cell lung cancer.
- Conditions
- Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT07718672
- Testing
- Biospecimen Collection, Computed Tomography, Lymph Node Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Roswell Park Cancer Institute
Solid Tumors With Oligometastatic Spread
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases
This is a prospective Phase II study.The purpose of this study is to monitor the side effects and treatment outcomes of delivering higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the…
- Trial name
- 5fr SBRT (NCT01761929)
- Testing
- Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
- Where
- Canada
- Volunteers
- 138 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife
Giving a higher dose of radiation to the dominant tumour nodule within the prostate is hypothesized to improve tumour control. This trial will assess whether this technique, delivered in 5 treatments, can be delivered without…
- Trial name
- SPARC (NCT02145494)
- Testing
- Radiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Hepatocellular Carcinoma
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic resection or liver transplantation, but less than 20% of HCC patients are suitable for surgery.
- Trial name
- NCT01825824
- Testing
- Stereotactic ablative radiotherapy
- Where
- 7 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Korea Cancer Center Hospital
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic resection or liver transplantation, but less than 20% of HCC patients are suitable for surgery.
- Trial name
- NCT01850667
- Testing
- Stereotactic body radiotherapy
- Where
- 7 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Korea Cancer Center Hospital
Non-small Cell Lung Cancer
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
Radiation can induce immunogenic cell death, local release of inflammatory cytokines, and damage associated molecular patterns (DAMPs) resulting in local effects on endothelial cell expression of adhesion receptors, increased…
- Trial name
- SKYROCKET (NCT05034055)
- Testing
- atezolizumab / tiragolumab
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Yonsei University